Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Pops
Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?
Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a buy?
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
Key Takeaways Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' weight-loss drugs in government-backed healthcare plans.The proposal recommended drugs like Ozempic and Mounjaro be covered under Medicare and Medicaid,
Novo Nordisk, Eli Lilly shares up as Biden proposes obesity coverage
Investors were excited as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid. Novo called the move an important step forward for patients.
Amgen's Weight Loss Result Is a Win for Eli Lilly
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.
Amgen weight loss data ‘underwhelms,’ says Deutsche Bank
MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight loss appears to miss the Street’s bogey of 25% weight loss and will weigh down Amgen shares,
2h
Eli Lilly’s Stock Poised for Growth Amid Potential CMS Coverage for Zepbound
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
MarketWatch
19h
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Campaign US
1h
Chief corporate brand officer Lina Polimeni on Eli Lilly’s ‘big evolution’ in marketing
Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the company’s marketing, shifting its focus to the Lilly brand, its patients and an ...
2d
on MSN
Eli Lilly’s (LLY) Breakthroughs: Hedge Funds’ New Healthcare Favorite
We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...
1d
Eli Lilly Stock Is Rising Tuesday: What's Going On?
Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to ...
1d
on MSN
These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Best Buy, Rivian, NRG Energy, Kohl’s, Semtech, and More
Stock futures declined Tuesday after President-elect Donald Trump said soon after he takes office he would enact a 25% tariff ...
4d
Eli Lilly: Steep Pullback, Still Compelling Here
LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...
ALS News Today
1d
Lilly to develop ALS therapies against targets ID’d with Verge tech
The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Zepbound
Joe Biden
Novo Nordisk
Amgen
U.S. Securities and Exchange Commission
Feedback